Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease (PEG-IFN-SA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01605513
Recruitment Status : Completed
First Posted : May 25, 2012
Last Update Posted : January 26, 2016
Information provided by (Responsible Party):
Yanhua Ding, First Hospital of Jilin University

Brief Summary:
The purpose of this study is to determine whether PEG-IFN-SA is safe, tolerant and effective in the treatment of HCV patients.

Condition or disease Intervention/treatment Phase
Hepatitis C Virus Drug: interferon Phase 1 Phase 2

Detailed Description:

Chronic infection with the hepatitis C virus (HCV) is a significant public health problem in china. Progressive liver disease, as a result of chronic HCV infection, usually develops slowly over 20-50 years and may lead to cirrhosis, hepatocellular carcinoma, liver failure and eventual death. Symptoms are typically mild and non-specific but nevertheless can cause a decrease in quality of life. Peginterferon alfa and ribavirin combination therapy is currently used in the china for treatment of chronic HCV. Successful treatment is considered to be attainment of a sustained virological response (SVR), defined as undetectable serum HCV ribonucleic acid (RNA) 6 months after cessation of treatment.

PEG-IFN-SA is a new recombinant interferon variant. Its N-terminus is modified by 20KD molecular weight single-methoxy polyethylene glycol (PEG). It consists of 171 amino acids before modification. PEG-IFN-SA is reorganization, unnatural existence and a new type of interferon (171Arg126Asp171IFN) after modification. The safety, tolerance and antiviral activity of PEG-IFN-SA was tested in adults with HCV infection.

PEG-IFN-SA was injected subcutaneously one times per week for 12 times. Peginterferon alfa-2a (Pegasys) is the positive control drug. 80 patients were randomly assigned to eight groups (PEG-IFN-SA 1.0μg/kg, Peginterferon alfa-2a 180 μg, PEG-IFN-SA 1.5 μg/kg,PEG-IFN-SA 2 μg/kg, PEG-IFN-SA 3 μg/kg,PEG-IFN-SA 1.5μg/kg + ribavirin 0.45g/bid group,Intergen 15μg/48hours for 7 times and ribavirin 0.45g/bid for 10 times).

Clinical and biological adverse effects were recorded every week such as headache, nausea and vomiting. HCV RNA level was tested by COBAS Taqman HCV Test system of Roche. Blood cell counts were tested using an automatic cell counter such as WBC, neutrophil, PLT and HGB. Biochemical indicators were tested by automatic biochemical analysis instrument.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Clinical Trial of PEG-IFN-SA in HCV Disease: Evidence for Drug Safety, Tolerance, and Antiviral Activity
Study Start Date : June 2011
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Interferon

Arm Intervention/treatment
Experimental: recombinant interferon
PEG-IFN-SA 1.0μg/kg for 12 times, Peginterferon alfa-2a 180 μg for 12 times, PEG-IFN-SA 1.5 μg/kg for 12 times, PEG-IFN-SA 2 μg/kg for 12 times, PEG-IFN-SA 3 μg/kg for 12 times, PEG-IFN-SA 1.5μg/kg + ribavirin 0.45g/bid group for 12 times, Intergen 15μg/48hours for 7 times, ribavirin 0.45g/bid for 10 times
Drug: interferon
PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.

Primary Outcome Measures :
  1. The proportions of absence of detectable HCV RNA after the 12th treatment [ Time Frame: 12th week ]

Secondary Outcome Measures :
  1. The proportions of absence of detectable HCV RNA after the 4th and 8th treatment [ Time Frame: 4th and 8th week ]
  2. HCV RNA levels after the 4th, 8th and 12th treatment [ Time Frame: the 4th, 8th and 12th week ]
  3. The test of Liver function [ Time Frame: the 2th, 4th, 6th, 8th,10th and 12th week ]
    Liver function test:TBIL,IBIL, ALT, AST;

  4. The test of Kidney function [ Time Frame: the 2th, 4th, 6th, 8th,10th and 12th week ]
    Kidney function test:BUN, CR;

  5. The test of Peripheral blood [ Time Frame: the 2th, 4th, 6th, 8th,10th and 12th week ]
    Peripheral blood detection:WBC, RBC, HgB,PLT, neutrophil

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. enrolled voluntarily, can understand and sign informed consent;
  2. More than 18 years and less than 65 years;
  3. body mass index (BMI) is at 18 - 26;
  4. anti-HCV antibodies and / or HCV RNA positive, and / or other evidence of chronic hepatitis C;
  5. HCV RNA level ≥ 2000IU/ml (or equal to this viral load);
  6. Women's urine pregnancy test was negative, and the subjects (male subjects) is willing to have no pregnancy plans at next 18 months. (7) ALT is within 6 times of the upper limit of normal

Exclusion Criteria:

  1. pregnant women, lactating women or plan to pregnant the next 18 months.
  2. mental disorder, including history of mental illness (especially the history of depression or depressive tendencies, epilepsy, etc.);
  3. The patient who received interferon therapy within the past six months or had no response at previous interferon therapy.
  4. The patient who used a strong immune regulator over two weeks with three months before screening, such as adrenocorticotropic hormone, thymosin of α1, thymus 5 peptide.
  5. The patient who used hepatotoxic drugs with 6 months before screening, such as dapsone, erythromycin, fluconazole, ketoconazole, rifampin.
  6. co-infection with other viruses (HAV, HBV, HEV, the HIV, EBV, CMV) .
  7. patients with a history of hepatocellular carcinoma (HCC), or may had hepatocellular carcinoma evidence, such as imaging of suspicious nodules, or AFP abnormal (AFP> 200ng/mL). FibroScan value greater than or equal to F3 at Screening
  8. other causes of liver disease: a chronic alcoholic hepatitis, drug-induced hepatitis, autoimmune liver disease, nonalcoholic steatohepatitis.
  9. autoimmune diseases, including psoriasis, systemic lupus erythematosus, thrombocytopenic purpura, and so on.
  10. heart and vascular system diseases, a history of myocarditis, hypertension, coronary heart disease, pathological arrhythmia, stroke.
  11. endocrine system diseases, including thyroid disease, diabetes, etc.
  12. pulmonary diseases, including invasive pulmonary disease, pneumonia, shortness of breath.
  13. Eye diseases, including retinopathy, retinopathy.
  14. chronic infectious disease history (history of tuberculosis).
  15. chronic kidney disease, serum creatinine level> 1.5 times upper limit of normal at screening, renal insufficiency, renal anemia history.
  16. anemia (including thalassemia, sickle hemoglobin, anemia), and hemophilia.
  17. peptic ulcer not controlled, colitis, pancreatitis and others.
  18. malignancies.
  19. peripheral blood checking: white blood cell count <3 × 109 / L; neutrophil count <1.5 x 109 / L; platelet count <90 × 109 / L; hemoglobin was less than the normal reference limit.
  20. serum total bilirubin> 2 times normal maximum reference value (ULN); serum albumin <35g / L; a history of decompensated cirrhosis evidence.
  21. evidence of drug addiction (including excessive alcohol intake, average alcohol consumption: men> 40g / day; women> 20g / day, equivalent to 50 degrees white wine 100ml / day and 50ml / day) within one year before screening.
  22. a serious history of drug and food allergy, especially towards the test drug (interferon, ribavirin).
  23. plans to accept an organ transplant or have organ transplant.
  24. participated other clinical trials before 3 months at screening
  25. The researchers judged the patients have other factors which may influence the experiment.

ribavirin exclusion criteria:

  1. women Hgb <12g/dl or men Hgb <13gdl at screening.
  2. anemia patients (eg, thalassemia, spherocytosis hyperlipidemia, gastrointestinal bleeding history) or suspected anemia patients.
  3. patients have a history of coronary artery disease or patients with cerebrovascular disease should not join this study, hemoglobin decline up to 4g/dl (it may be observed in the ribavirin treatment).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01605513

China, Jilin
Phase One Clinical Trial ward, First Hospital, Jilin University
Changchun, Jilin, China, 13021
Sponsors and Collaborators
First Hospital of Jilin University
Study Director: yanhua ding, associate professor First Hospital, Jilin University

Responsible Party: Yanhua Ding, associate professor, First Hospital of Jilin University Identifier: NCT01605513     History of Changes
Other Study ID Numbers: 2011L0901
First Posted: May 25, 2012    Key Record Dates
Last Update Posted: January 26, 2016
Last Verified: January 2016

Keywords provided by Yanhua Ding, First Hospital of Jilin University:
recombinant interferon, tolerated, effective

Additional relevant MeSH terms:
Hepatitis C
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Liver Diseases
Digestive System Diseases
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents